PubMed:33008453
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T1 | 61-65 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
| T2 | 72-85 | Body_part | denotes | lymphoblastic | http://purl.org/sig/ont/fma/fma83030 |
| T3 | 304-308 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
| T4 | 315-328 | Body_part | denotes | lymphoblastic | http://purl.org/sig/ont/fma/fma83030 |
| T5 | 504-512 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
| T6 | 955-960 | Body_part | denotes | chest | http://purl.org/sig/ont/fma/fma9576 |
| T7 | 1097-1103 | Body_part | denotes | plasma | http://purl.org/sig/ont/fma/fma62970 |
| T8 | 1549-1559 | Body_part | denotes | lymphocyte | http://purl.org/sig/ont/fma/fma62863 |
| T9 | 1565-1573 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
LitCovid-PD-UBERON
| Id | Subject | Object | Predicate | Lexical cue | uberon_id |
|---|---|---|---|---|---|
| T1 | 955-960 | Body_part | denotes | chest | http://purl.obolibrary.org/obo/UBERON_0001443 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T1 | 7-15 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T2 | 59-94 | Disease | denotes | B cell acute lymphoblastic leukemia | http://purl.obolibrary.org/obo/MONDO_0004947|http://purl.obolibrary.org/obo/MONDO_0020511 |
| T4 | 66-94 | Disease | denotes | acute lymphoblastic leukemia | http://purl.obolibrary.org/obo/MONDO_0004967 |
| T5 | 72-94 | Disease | denotes | lymphoblastic leukemia | http://purl.obolibrary.org/obo/MONDO_0001018 |
| T6 | 86-94 | Disease | denotes | leukemia | http://purl.obolibrary.org/obo/MONDO_0005059 |
| T7 | 96-104 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T8 | 196-206 | Disease | denotes | infections | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T9 | 302-337 | Disease | denotes | B cell acute lymphoblastic leukemia | http://purl.obolibrary.org/obo/MONDO_0004947|http://purl.obolibrary.org/obo/MONDO_0020511 |
| T11 | 309-337 | Disease | denotes | acute lymphoblastic leukemia | http://purl.obolibrary.org/obo/MONDO_0004967 |
| T12 | 315-337 | Disease | denotes | lymphoblastic leukemia | http://purl.obolibrary.org/obo/MONDO_0001018 |
| T13 | 329-337 | Disease | denotes | leukemia | http://purl.obolibrary.org/obo/MONDO_0005059 |
| T14 | 465-473 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T15 | 585-593 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T16 | 664-672 | Disease | denotes | leukemia | http://purl.obolibrary.org/obo/MONDO_0005059 |
| T17 | 749-757 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T18 | 836-844 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T19 | 845-854 | Disease | denotes | pneumonia | http://purl.obolibrary.org/obo/MONDO_0005249 |
| T20 | 860-871 | Disease | denotes | lymphopenia | http://purl.obolibrary.org/obo/MONDO_0003783 |
| T21 | 1237-1245 | Disease | denotes | leukemia | http://purl.obolibrary.org/obo/MONDO_0005059 |
| T22 | 1372-1380 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T23 | 1486-1494 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T24 | 1641-1649 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 16-21 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
| T2 | 59-65 | http://purl.obolibrary.org/obo/CL_0000236 | denotes | B cell |
| T3 | 107-110 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
| T4 | 240-241 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T5 | 250-251 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T6 | 264-270 | http://purl.obolibrary.org/obo/UBERON_0003100 | denotes | female |
| T7 | 302-308 | http://purl.obolibrary.org/obo/CL_0000236 | denotes | B cell |
| T8 | 354-355 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T9 | 497-498 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T10 | 827-828 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T11 | 955-960 | http://www.ebi.ac.uk/efo/EFO_0000965 | denotes | chest |
| T12 | 1097-1103 | http://purl.obolibrary.org/obo/UBERON_0001969 | denotes | plasma |
| T13 | 1116-1118 | http://purl.obolibrary.org/obo/CLO_0001382 | denotes | 48 |
| T14 | 1399-1400 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T1 | 391-400 | Chemical | denotes | rituximab | http://purl.obolibrary.org/obo/CHEBI_64357 |
| T2 | 402-412 | Chemical | denotes | cytarabine | http://purl.obolibrary.org/obo/CHEBI_28680 |
| T3 | 418-427 | Chemical | denotes | dasatinib | http://purl.obolibrary.org/obo/CHEBI_49375|http://purl.obolibrary.org/obo/CHEBI_70839 |
| T5 | 689-698 | Chemical | denotes | rituximab | http://purl.obolibrary.org/obo/CHEBI_64357 |
| T6 | 700-710 | Chemical | denotes | cytarabine | http://purl.obolibrary.org/obo/CHEBI_28680 |
| T7 | 716-725 | Chemical | denotes | dasatinib | http://purl.obolibrary.org/obo/CHEBI_49375|http://purl.obolibrary.org/obo/CHEBI_70839 |
| T9 | 1053-1061 | Chemical | denotes | steroids | http://purl.obolibrary.org/obo/CHEBI_35341 |
| T10 | 1133-1139 | Chemical | denotes | oxygen | http://purl.obolibrary.org/obo/CHEBI_25805 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-95 | Sentence | denotes | Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia. |
| T2 | 96-223 | Sentence | denotes | SARS-CoV-2 has infected millions of people worldwide, but little is known at this time about second infections or reactivation. |
| T3 | 224-428 | Sentence | denotes | Here, we report a case of a 55-year-old female undergoing treatment for CD20+ B cell acute lymphoblastic leukemia who experienced a viral reactivation after receiving rituximab, cytarabine, and dasatinib. |
| T4 | 429-609 | Sentence | denotes | She was initially hospitalized with COVID-19 in April and developed a high antibody titer with two negative nasal polymerase chain reaction (PCR) swabs for SARS-CoV-2 on discharge. |
| T5 | 610-726 | Sentence | denotes | After recovery, she resumed treatment in June for her leukemia, which included rituximab, cytarabine, and dasatinib. |
| T6 | 727-812 | Sentence | denotes | She promptly lost her COVID-19 antibodies, and her nasal PCR turned positive in June. |
| T7 | 813-1039 | Sentence | denotes | She developed a severe COVID-19 pneumonia with lymphopenia, high inflammatory markers, and characteristic bilateral ground-glass opacities on chest CT, requiring high-flow nasal cannula and transfer to the intensive care unit. |
| T8 | 1040-1140 | Sentence | denotes | She received steroids, anticoagulation, and convalescent plasma, and within 48 h she was off oxygen. |
| T9 | 1141-1204 | Sentence | denotes | She was discharged home in stable condition several days later. |
| T10 | 1205-1422 | Sentence | denotes | Given the short time frame from leukemia treatment to PCR positivity and the low case rate in mid-June in New York City, reinfection appears to have been unlikely and SARS-CoV-2 reactivation is a possible explanation. |
| T11 | 1423-1665 | Sentence | denotes | This case illustrates the risks of treating recently recovered COVID-19 patients with immunosuppressive therapy, particularly lymphocyte- and antibody-depleting therapy, and raises new questions about the potential of SARS-CoV-2 reactivation. |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 2 | 7-21 | Species | denotes | COVID-19 virus | Tax:2697049 |
| 3 | 72-94 | Disease | denotes | lymphoblastic leukemia | MESH:D054198 |
| 28 | 96-106 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 29 | 132-138 | Species | denotes | people | Tax:9606 |
| 30 | 196-206 | Disease | denotes | infections | MESH:D007239 |
| 31 | 296-300 | Gene | denotes | CD20 | Gene:54474 |
| 32 | 315-337 | Disease | denotes | lymphoblastic leukemia | MESH:D054198 |
| 33 | 391-400 | Chemical | denotes | rituximab | MESH:D000069283 |
| 34 | 402-412 | Chemical | denotes | cytarabine | MESH:D003561 |
| 35 | 418-427 | Chemical | denotes | dasatinib | MESH:D000069439 |
| 36 | 465-473 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 37 | 585-595 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 38 | 664-672 | Disease | denotes | leukemia | MESH:D007938 |
| 39 | 689-698 | Chemical | denotes | rituximab | MESH:D000069283 |
| 40 | 700-710 | Chemical | denotes | cytarabine | MESH:D003561 |
| 41 | 716-725 | Chemical | denotes | dasatinib | MESH:D000069439 |
| 42 | 749-757 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 43 | 836-854 | Disease | denotes | COVID-19 pneumonia | MESH:C000657245 |
| 44 | 860-871 | Disease | denotes | lymphopenia | MESH:D008231 |
| 45 | 1053-1061 | Chemical | denotes | steroids | MESH:D013256 |
| 46 | 1133-1139 | Chemical | denotes | oxygen | MESH:D010100 |
| 47 | 1237-1245 | Disease | denotes | leukemia | MESH:D007938 |
| 48 | 1372-1382 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 49 | 1486-1494 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 50 | 1495-1503 | Species | denotes | patients | Tax:9606 |
| 51 | 1641-1651 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T1 | 66-94 | Phenotype | denotes | acute lymphoblastic leukemia | http://purl.obolibrary.org/obo/HP_0006721 |
| T2 | 309-337 | Phenotype | denotes | acute lymphoblastic leukemia | http://purl.obolibrary.org/obo/HP_0006721 |
| T3 | 664-672 | Phenotype | denotes | leukemia | http://purl.obolibrary.org/obo/HP_0001909 |
| T4 | 845-854 | Phenotype | denotes | pneumonia | http://purl.obolibrary.org/obo/HP_0002090 |
| T5 | 860-871 | Phenotype | denotes | lymphopenia | http://purl.obolibrary.org/obo/HP_0001888 |
| T6 | 1237-1245 | Phenotype | denotes | leukemia | http://purl.obolibrary.org/obo/HP_0001909 |
Inflammaging
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-95 | Sentence | denotes | Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia. |
| T2 | 96-223 | Sentence | denotes | SARS-CoV-2 has infected millions of people worldwide, but little is known at this time about second infections or reactivation. |
| T3 | 224-428 | Sentence | denotes | Here, we report a case of a 55-year-old female undergoing treatment for CD20+ B cell acute lymphoblastic leukemia who experienced a viral reactivation after receiving rituximab, cytarabine, and dasatinib. |
| T4 | 429-609 | Sentence | denotes | She was initially hospitalized with COVID-19 in April and developed a high antibody titer with two negative nasal polymerase chain reaction (PCR) swabs for SARS-CoV-2 on discharge. |
| T5 | 610-726 | Sentence | denotes | After recovery, she resumed treatment in June for her leukemia, which included rituximab, cytarabine, and dasatinib. |
| T6 | 727-812 | Sentence | denotes | She promptly lost her COVID-19 antibodies, and her nasal PCR turned positive in June. |
| T7 | 813-1039 | Sentence | denotes | She developed a severe COVID-19 pneumonia with lymphopenia, high inflammatory markers, and characteristic bilateral ground-glass opacities on chest CT, requiring high-flow nasal cannula and transfer to the intensive care unit. |
| T8 | 1040-1140 | Sentence | denotes | She received steroids, anticoagulation, and convalescent plasma, and within 48 h she was off oxygen. |
| T9 | 1141-1204 | Sentence | denotes | She was discharged home in stable condition several days later. |
| T10 | 1205-1422 | Sentence | denotes | Given the short time frame from leukemia treatment to PCR positivity and the low case rate in mid-June in New York City, reinfection appears to have been unlikely and SARS-CoV-2 reactivation is a possible explanation. |
| T11 | 1423-1665 | Sentence | denotes | This case illustrates the risks of treating recently recovered COVID-19 patients with immunosuppressive therapy, particularly lymphocyte- and antibody-depleting therapy, and raises new questions about the potential of SARS-CoV-2 reactivation. |
| T1 | 0-95 | Sentence | denotes | Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia. |
| T2 | 96-223 | Sentence | denotes | SARS-CoV-2 has infected millions of people worldwide, but little is known at this time about second infections or reactivation. |
| T3 | 224-428 | Sentence | denotes | Here, we report a case of a 55-year-old female undergoing treatment for CD20+ B cell acute lymphoblastic leukemia who experienced a viral reactivation after receiving rituximab, cytarabine, and dasatinib. |
| T4 | 429-609 | Sentence | denotes | She was initially hospitalized with COVID-19 in April and developed a high antibody titer with two negative nasal polymerase chain reaction (PCR) swabs for SARS-CoV-2 on discharge. |
| T5 | 610-726 | Sentence | denotes | After recovery, she resumed treatment in June for her leukemia, which included rituximab, cytarabine, and dasatinib. |
| T6 | 727-812 | Sentence | denotes | She promptly lost her COVID-19 antibodies, and her nasal PCR turned positive in June. |
| T7 | 813-1039 | Sentence | denotes | She developed a severe COVID-19 pneumonia with lymphopenia, high inflammatory markers, and characteristic bilateral ground-glass opacities on chest CT, requiring high-flow nasal cannula and transfer to the intensive care unit. |
| T8 | 1040-1140 | Sentence | denotes | She received steroids, anticoagulation, and convalescent plasma, and within 48 h she was off oxygen. |
| T9 | 1141-1204 | Sentence | denotes | She was discharged home in stable condition several days later. |
| T10 | 1205-1422 | Sentence | denotes | Given the short time frame from leukemia treatment to PCR positivity and the low case rate in mid-June in New York City, reinfection appears to have been unlikely and SARS-CoV-2 reactivation is a possible explanation. |
| T11 | 1423-1665 | Sentence | denotes | This case illustrates the risks of treating recently recovered COVID-19 patients with immunosuppressive therapy, particularly lymphocyte- and antibody-depleting therapy, and raises new questions about the potential of SARS-CoV-2 reactivation. |